Mavrilimumab - CISMeF

Preferred Label : Mavrilimumab;

NCIt synonyms : Immunoglobulin G4, Anti-(Human Granulocyte-Macrophage Colony-Stimulating-Factor Receptor alpha-Chain) (Human Monoclonal CAM-3001 Heavy Chain), Disulfide with Human Monoclonal CAM-3001 lambda-Chain, Dimer;

NCIt definition : A human IgG4 monoclonal antibody targeting the alpha chain of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-Ra), with potential immunomodulating activity. Mavrilimumab binds to GM-CSF-Ra and inhibits the GM-CSF-mediated pathway. This may inhibit inflammation. GM-CSF and its receptor are upregulated in a number of autoimmune diseases and play a key role in the activation, differentiation and function of both granulocytes and monocytes.;

UNII : 1158JD1P9A;

CAS number : 1085337-57-0;

Molecule name : CAM-3001;

Détails

Origin ID

C95788;

UMLS CUI

C2987425;

Currated CISMeF NLP mapping
- Mavrilimumab [SMS substance]
- mavrilimumab [MeSH concept]
- mavrilimumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- mavrilimumab [MeSH Supplementary Concept]
- mavrilimumab [MeSH concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients